Under 10% of individuals that would benefit from weight-loss injections such as Wegovy have access to them, states the WHO as it issues its initial guidance on the therapies.
Considering over a billion people worldwide currently living with obesity, it is urging increased and just access to these injectable treatments.
Based on forecasts, in excess of 2,000,000,000 will be living with obesity by 2030 if no action is taken.
"Our latest guidance acknowledges that excess weight is a lifelong illness that can be addressed with comprehensive and ongoing care," said the agency's head Tedros Adhanom Ghebreyesus.
Substantial prices, constrained manufacturing, and distribution challenges are key obstacles to widespread access to the jabs that can help people shift considerable weight, explains the organization.
Weight-Loss Drug Supply Crisis
Despite the present most favorable outlook, the production of these medications would only suffice for approximately 100 million people – fewer than 10% of eligible patients, per the health organization.
The recommendation calls on governments and firms to increase access, by measures such as licensing agreements.
The intellectual property rights on the active ingredient – the core component of a leading brand – is set to lapse in several countries in 2026.
How Obesity Jabs Work
GLP-1 drugs mimick a biological compound to reduce digestion speed, reduce hunger and increase feelings of fullness so people reduce food intake.
Patients usually start to lose weight within a few weeks of commencing the weekly injections.
Evidence points to users may put most of the weight back on after a year of stopping the drug, as their typical food cravings return.
Being overweight or obese elevates your chance for experiencing medical conditions, including diabetes, heart disease, brain attack, and some malignancies.
Excess weight affects people in all nations and was linked to over three and a half million fatalities worldwide in 2024, according to the WHO.
